Key Points
- Jennifer Humes, Roivant's CAO, sold 13,538 shares on April 8 at an average price of $28.37, receiving about $384,073 and reducing her holding by 13.85% to 84,191 shares, per an SEC filing.
- Roivant shares traded near $28.21 (52‑week range $9.57–$30.33) with a market cap of roughly $20.19 billion and a negative P/E of -24.11; the 50‑ and 200‑day moving averages are about $27.40 and $22.63, respectively.
- Analyst and institutional sentiment is broadly positive—nine Buys, one Hold and one Sell yield a consensus "Moderate Buy" with a $29.50 target—and institutional/hedge funds own about 64.76% of the stock, including recent additions by Goldman Sachs and UBS.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CAO Jennifer Humes sold 13,538 shares of the firm's stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total value of $384,073.06. Following the completion of the transaction, the chief accounting officer owned 84,191 shares in the company, valued at approximately $2,388,498.67. This trade represents a 13.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Roivant Sciences Stock Performance
Shares of Roivant Sciences stock opened at $28.21 on Friday. Roivant Sciences Ltd. has a one year low of $9.57 and a one year high of $30.33. The company has a market cap of $20.19 billion, a price-to-earnings ratio of -24.11 and a beta of 1.20. The business's 50 day moving average price is $27.40 and its 200 day moving average price is $22.63.
Institutional Investors Weigh In On Roivant Sciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ROIV. Goldman Sachs Group Inc. raised its position in Roivant Sciences by 15.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company's stock valued at $24,553,000 after purchasing an additional 324,764 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Roivant Sciences by 1.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company's stock valued at $24,678,000 after purchasing an additional 34,341 shares during the period. American Century Companies Inc. raised its position in Roivant Sciences by 1.9% in the second quarter. American Century Companies Inc. now owns 89,625 shares of the company's stock valued at $1,010,000 after purchasing an additional 1,689 shares during the period. Russell Investments Group Ltd. raised its position in Roivant Sciences by 149.9% in the second quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company's stock valued at $129,000 after purchasing an additional 6,879 shares during the period. Finally, M&T Bank Corp raised its position in Roivant Sciences by 10.2% in the second quarter. M&T Bank Corp now owns 12,802 shares of the company's stock valued at $144,000 after purchasing an additional 1,181 shares during the period. Hedge funds and other institutional investors own 64.76% of the company's stock.
Analyst Ratings Changes
A number of equities analysts recently commented on ROIV shares. Jefferies Financial Group reiterated a "buy" rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Citigroup lifted their price objective on Roivant Sciences from $26.00 to $35.00 and gave the stock a "buy" rating in a research report on Tuesday, February 10th. The Goldman Sachs Group lifted their price objective on Roivant Sciences from $24.00 to $33.00 and gave the stock a "buy" rating in a research report on Monday, December 15th. HC Wainwright lifted their price objective on Roivant Sciences from $33.00 to $34.00 and gave the stock a "buy" rating in a research report on Wednesday, March 4th. Finally, Guggenheim lifted their price objective on Roivant Sciences from $28.00 to $30.00 and gave the stock a "buy" rating in a research report on Monday, February 9th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.50.
View Our Latest Report on Roivant Sciences
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
